The practice of cord blood banking, where stem cells from a newborn’s umbilical cord are preserved for potential future medical use, has gained significant traction worldwide. However, adoption rates, regulatory frameworks, and public awareness vary significantly across geographic regions. In some areas, robust public and private banking systems drive widespread participation, while in others, the practice remains nascent, shaped by cultural attitudes, healthcare infrastructure, and policy.
In addition to being complex industry, it is also a recent industry. It was not until 1974 that it was first proposed that progenitor cells were present in human cord blood and 1983 that umbilical cord blood was proposed as an alternative source of stem cells for transplant. In 1988, the first successful cord blood transplant occurred, but it was not until 1995 that the first private cord blood bank began operations.
Since 1988, stem cells from umbilical blood have been used in more than 40,000 transplants worldwide.
